Duraquin (BioDeep_00000684907)

   


代谢物信息卡片


quinidine gluconate

化学式: C26H36N2O9 (520.2420686)
中文名称: 奎尼丁葡萄糖酸盐
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: COC1=CC2=C(C=CN=C2C=C1)C(C3CC4CCN3CC4C=C)O.C(C(C(C(C(C(=O)O)O)O)O)O)O
InChI: 2-,3-,4+,5-/m01/s1

描述信息

D000890 - Anti-Infective Agents > D000977 - Antiparasitic Agents > D000981 - Antiprotozoal Agents
C254 - Anti-Infective Agent > C276 - Antiparasitic Agent > C277 - Antiprotozoal Agent
C93038 - Cation Channel Blocker

同义名列表

2 个代谢物同义名

quinidine gluconate; Duraquin



数据库引用编号

7 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

0 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有:

  • PubMed: 来源于PubMed文献库中的文献信息,我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表,这个列表按照代谢物同时出现的文献数量降序排序,取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘,得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序,取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中,存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称,可以跳转到相关代谢物的信息页面。



文献列表

  • Hania Habeeb, Jill R Ripper, Alice Cohen, Patrick B Hinfey. A case of imported severe plasmodium falciparum malaria in the emergency department and the current role of exchange transfusion treatment. The Journal of emergency medicine. 2013 Feb; 44(2):e211-5. doi: 10.1016/j.jemermed.2012.02.051. [PMID: 22609412]
  • Ahmed M Alkhunaizi, Jaffar A Al-Tawfiq, Mohannad H Al-Shawaf. Transfusion-transmitted malaria in a kidney transplant recipient. How safe is our blood transfusion?. Saudi medical journal. 2008 Feb; 29(2):293-5. doi: NULL. [PMID: 18246245]
  • V F Mauro, L S Mauro, T D Fraker, P N Temesy-Armos, P Somani. Effect of aluminum hydroxide gel on quinidine gluconate absorption. DICP : the annals of pharmacotherapy. 1990 Mar; 24(3):252-4. doi: 10.1177/106002809002400308. [PMID: 2316233]
  • M N Martinez, F R Pelsor, V P Shah, J P Skelly, I L Honigberg, S M Hemingway, J M Gallo, J A Kotzan, R Zaman, W J Brown. Effect of dietary fat content on the bioavailability of a sustained release quinidine gluconate tablet. Biopharmaceutics & drug disposition. 1990 Jan; 11(1):17-29. doi: 10.1002/bdd.2510110103. [PMID: 2322634]
  • K D Miller, A E Greenberg, C C Campbell. Treatment of severe malaria in the United States with a continuous infusion of quinidine gluconate and exchange transfusion. The New England journal of medicine. 1989 Jul; 321(2):65-70. doi: 10.1056/nejm198907133210201. [PMID: 2659994]
  • B H Ackerman, K M Olsen, E E Kennedy, E H Taylor, B H Chen, D Jordan, D J Ackerman. Disposition of 3-hydroxyquinidine in patients receiving initial intravenous quinidine gluconate for electrophysiology testing of ventricular tachycardia. DICP : the annals of pharmacotherapy. 1989 May; 23(5):375-8. doi: 10.1177/106002808902300504. [PMID: 2728524]
  • B Hughes, J E Dyer, A B Schwartz. Increased procainamide plasma concentrations caused by quinidine: a new drug interaction. American heart journal. 1987 Oct; 114(4 Pt 1):908-9. doi: 10.1016/0002-8703(87)90809-x. [PMID: 3661379]
  • G J Burckart, J Marin-Garcia. Quinidine dosage in children using population estimates. Pediatric cardiology. 1986; 6(5):269-73. doi: NULL. [PMID: 3725633]
  • A Squire, M E Goldman, J Kupersmith, E H Stern, V Fuster, P Schweitzer. Long-term antiarrhythmic therapy. Problem of low drug levels and patient noncompliance. The American journal of medicine. 1984 Dec; 77(6):1035-8. doi: 10.1016/0002-9343(84)90184-0. [PMID: 6507457]
  • M A Zinny, W V Taggart. Bioavailability of two manufacturers' sustained-release quinidine gluconate tablets at steady state. Clinical therapeutics. 1984; 7(1):22-7. doi: NULL. [PMID: 6518461]
  • J M St-Onge, G Sirois, M A Gagnon. Urinary excretion kinetics of intact quinidine and 3-OH-quinidine after oral administration of a single oral dose of quinidine gluconate in the fasting and non-fasting state. European journal of drug metabolism and pharmacokinetics. 1983 Oct; 8(4):363-72. doi: 10.1007/bf03188768. [PMID: 6673973]
  • S M McGuirk, W W Muir, R A Sams, D M Rings. Atrial fibrillation in cows: clinical findings and therapeutic considerations. Journal of the American Veterinary Medical Association. 1983 Jun; 182(12):1380-6. doi: NULL. [PMID: 6874503]
  • N J Warner, E B Leahey, T J Hougen, J T Bigger, T W Smith. Tissue digoxin concentrations during the quinidine-digoxin interaction. The American journal of cardiology. 1983 Jun; 51(10):1717-21. doi: 10.1016/0002-9149(83)90217-5. [PMID: 6858881]
  • W V Taggart, W Holyoak. Steady-state bioavailability of two sustained-release quinidine preparations: quinidine gluconate versus quinidine sulfate. Clinical therapeutics. 1983; 5(4):357-64. doi: . [PMID: 6871920]
  • A Vidaurri, G Pastelín, R Méndez, M Cárdenas. [Treatment of atrial fibrillation using intravenous infusion of quinidine]. Archivos del Instituto de Cardiologia de Mexico. 1983 Jan; 53(1):5-11. doi: NULL. [PMID: 6223605]
  • J Russo, M E Russo, R A Smith, L K Pershing. Assessment of quinidine gluconate for nonlinear kinetics following chronic dosing. Journal of clinical pharmacology. 1982 May; 22(5-6):264-70. doi: 10.1002/j.1552-4604.1982.tb02672.x. [PMID: 7107973]
  • M C Meyer, A B Straughn, P Lieberman, J Jacob. Serious bioavailability problems with a generic prolonged-release quinidine gluconate product. Journal of clinical pharmacology. 1982 Feb; 22(2-3):131-4. doi: 10.1002/j.1552-4604.1982.tb02660.x. [PMID: 7068936]
  • H Isaacs, J J Heffron, M Badenhorst. 'Picture frame' fibres in a carrier of the trait for malignant hyperpyrexia. South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde. 1975 Nov; 49(46):1923-6. doi: NULL. [PMID: 795]